Breast Cancer Targeted Therapies and Immunotherapies
- Breast cancer targeted therapies uses medicines to block specific proteins or genes that help cancer cells grow and spread.
- Biologics approved for use in healthcare include monoclonal antibodies and antibody-drug conjugates both combined with chemotherapy.
Every year on October 15, the international scientific and medical community celebrates European Breast Cancer Awareness Day. Originally established in 2008 by Europa Donna (The European Breast Cancer Coalition), this observance highlights the global imperative of prevention, early detection, and innovative medical care.
The scale of the challenge is enormous. According to the World Health Organization (WHO), approximately 2.4 million women worldwide were diagnosed with breast cancer in 2024, and an estimated 694,000 died from the disease.1 It is the most common cancer among women in 164 of 186 countries.2 The European Cancer Information System (ECIS) estimated 373,874 new cases in women in the European Union and 94,998 deaths in 2024, which means almost 30% of all cancers diagnosed in women and the leading cause of cancer death among them.3 The trajectory is sobering. Unless prevention and care improve, International Agency for Research on Cancer (IARC) projects 3.2 million new cases and 1.1 million deaths per year worldwide by 2050.4
Biologic Therapies for Advanced Breast Cancer
Breast cancer is not a single disease but a family of molecularly distinct diseases, among them hormone receptor-positive, HER2-positive and triple-negative tumors, and it is precisely this diversity that has made it a proving ground for precision oncology, where a drug is matched to the biology of the tumor rather than to its location in the body. Biological drugs target the specific proteins, receptors, or cellular processes involved in the development of cancer.5
Many of these medicines are complex proteins manufactured using living cells, frequently genetically engineered mammalian cell lines. The cells are cultivated in carefully controlled bioreactors, where they produce therapeutic proteins that are subsequently purified, characterized, and formulated under stringent pharmaceutical quality standards. In breast cancer targeted therapies, these biologics include monoclonal antibodies (mAbs), and antibody-drug conjugates (ADCs).
Monoclonal Antibodies Breast Cancer Targeted Therapies
Monoclonal antibodies are proteins designed to recognize a specific molecular structure called an antigen. Most conventional therapeutic antibodies consist of two identical heavy chains (H) and two identical light chains (L). The lower stem, called the crystallizable fragment (Fc region), can interact with receptors on immune cells. Their two upper arms contain antigen-binding fragments (Fab regions), which recognize a specific site, or epitope, on a target molecule. Complementarity-determining regions (CDRs) are particularly important segments that enable specific antigen binding. These are hypervariable loops in the variable domains of antibodies that form the actual antigen-binding site (Fig. 1).
This structure allows an antibody to perform two complementary functions: recognize a molecular target and recruit immune mechanisms. Among these, the most important are complement-dependent cytotoxicity (CDC), in which complement cascade activation leads to the formation of pores in the cell membrane and cell lysis, and antibody-dependent cellular cytotoxicity (ADCC), in which natural killer (NK) cells participate in destroying antibody-coated cancer cells.6

Modern therapeutic antibodies are humanised or fully human to limit immunogenicity. Their Fc can be deliberately engineered, for instance by choosing the IgG1 subclass for strong effector function or IgG4 for a quieter profile, to match the intended mechanism. The following antibody-based drugs are highly effective and are among the key breast cancer targeted therapies.
Trastuzumab
Trastuzumab is a humanized IgG1 that recognises subdomain IV of the human epidermal growth factor receptor 2 (HER2) extracellular domain, the membrane-proximal region closest to the cell surface. Approximately 20-30% of primary breast cancer cases overexpress the HER2 receptor. It is associated with a poorer prognosis and more aggressive tumor growth, resulting in shorter survival compared to tumors without HER2 overexpression.7 By attaching to HER2, trastuzumab can reduce receptor-dependent growth signaling and inhibit proteolytic cleavage of the receptor’s extracellular portion, limiting formation of the constitutively active p95HER2 fragment. These effects influence downstream pathways associated with cell survival and proliferation, including PI3K/AKT signaling.8 Simultaneously, the antibody’s Fc region can interact with Fcγ receptors on NK cells, effectively mediates ADCC.9
The introduction of trastuzumab fundamentally changed the prognosis of HER2-positive breast cancer. In an early pivotal study of metastatic disease, adding trastuzumab to chemotherapy extended median overall survival from 20.3 to 25.1 months, providing the first convincing clinical evidence that HER2 could be successfully targeted.7 Its longer-term benefits were subsequently demonstrated in early-stage breast cancer. Meta-analysis combining individual patient data from 13,864 women enrolled in seven randomized clinical trials, found that adding trastuzumab to chemotherapy reduced the relative risk of breast cancer recurrence by approximately 34% and breast cancer mortality by approximately 33%.10 These results established HER2 inhibition as one of the most important breakthroughs in targeted oncology.
Following promising results from clinical trials, trastuzumab was ready to enter the market. Herceptin was approved by the U.S. Food and Drug Administration (FDA) in 1998 as the first targeted monoclonal antibody for treating HER2-positive metastatic breast cancer. The European Medicines Agency (EMA) approved the drug in August 2000. In 2006, approval was expanded to early-stage HER2-positive breast cancer after surgery (adjuvant setting), which significantly reduced recurrence and mortality rates. It was included in the treatment in combination with anthracycline- and taxane-based chemotherapy.11 The success of trastuzumab paved the way for new combination treatment and antibody-drug conjugates. Trastuzumab biosimilars have expanded global access to effective breast cancer targeted therapies.12
Pertuzumab
Pertuzumab was designed as the mechanistic complement of trastuzumab. It is a humanised IgG1 that binds subdomain II of the HER2 extracellular domain, often described as the dimerisation arm, a region quite distant from the trastuzumab epitope in subdomain IV.13 By occupying this arm, pertuzumab sterically prevents HER2 from pairing with HER3, EGFR and HER4, including the ligand-activated pairs. The HER2–HER3 interaction is a potent activator of the PI3K/AKT pathway, which promotes malignant cell growth and survival.14 By preventing receptor dimerization, pertuzumab interrupts a signaling mechanism that trastuzumab does not completely block. Because the two antibodies occupy different epitopes, they can bind the same receptor simultaneously, and together they combine more complete signal blockade with stronger recruitment of NK cells through two Fc regions rather than one.
Dual HER2 blockade combining pertuzumab with trastuzumab and a taxane (docetaxel or paclitaxel) represents the universal first-line standard of care for HER2-positive metastatic breast cancer. The clinical significance of dual HER2 blockade was established in the landmark CLEOPATRA trial. That clinical study evaluated pertuzumab combined with trastuzumab and docetaxel in previously untreated metastatic HER2-positive breast cancer. The final analysis demonstrated median overall survival of 57.1 months with pertuzumab, compared with 40.8 months without it, corresponding to an improvement of more than 16 months. 37% of patients in the pertuzumab arm still alive at eight years compared with 23% in the control arm, a result that was described as unprecedented in this disease.15
Pertuzumab, marketed as Perjeta, received approval from the FDA on June 2012, and the EMA on April 2013, for first-line metastatic HER2-positive breast cancer. It subsequently received accelerated FDA approval in 2013 for neoadjuvant treatment of early-stage HER2-positive breast cancer. In November 2025 the FDA approved Poherdy, the first pertuzumab biosimilar.16
Margetuximab
Margetuximab represents an attempt to improve an established antibody through advanced protein engineering. Like trastuzumab, it recognizes an epitope in subdomain IV of the HER2 extracellular region, but its Fc region has been deliberately modified. These modifications increase binding to the activating Fcγ receptor IIIa (CD16A) and reduce binding to the inhibitory Fcγ receptor IIb (CD32B). CD16A is expressed on NK cells and participates in ADCC, meaning that stronger interactions between the antibody and this receptor can potentially enhance immune-mediated tumor destruction.17 Margetuximab illustrates the potential of Fc engineering. The clinical aim was to strengthen ADCC, in particular in patients who carry the low-affinity CD16A-158F variant. This variant is found in roughly 85% of the population and of the patients in the pivotal trial and has been associated with a weaker response to trastuzumab.
Margetuximab with chemotherapy improved median progression-free survival modestly, from 4.9 to 5.8 months. However, the final overall survival analysis showed no statistically significant advantage: 21.6 months with margetuximab versus 21.9 months with trastuzumab.18
The FDA approved margetuximab under the brand name Margenza in December 2020, in combination with chemotherapy for patients with metastatic HER2-positive breast cancer previously treated with at least two anti-HER2 regimens, including at least one for metastatic disease.19

Pembrolizumab
Pembrolizumab is a humanized IgG4 monoclonal antibody targeting the PD-1 receptor on immune cells, particularly activated T lymphocytes. Under normal circumstances, binding of PD-L1 or PD-L2 to PD-1 transmits an inhibitory signal that reduces T-cell activity and helps prevent uncontrolled immune responses. Tumors can exploit this mechanism to escape immune surveillance. Pembrolizumab blocks PD-1 interactions with these ligands, helping restore the ability of tumor-reactive T cells to attack malignant cells. Its IgG4 backbone, with a stabilised hinge, has little capacity to trigger ADCC or complement, and this is a deliberate design choice. The target sits on the very T cells the drug is meant to rescue, so an antibody that destroyed them would defeat its own purpose.21
This therapy is specifically intended for high-risk, early-stage, and certain advanced or metastatic forms of triple-negative breast cancer (TNBC). Two pivotal trials established pembrolizumab’s role in breast cancer. In KEYNOTE-355, patients with previously untreated advanced TNBC whose tumors expressed PD-L1 at a combined positive score (CPS) of at least 10 achieved median overall survival of 23.0 months versus 16.1 months with chemotherapy alone.22 In early-stage TNBC, KEYNOTE-522 evaluated pembrolizumab administered before surgery with chemotherapy and continued afterward. The final analysis showed seven-year overall survival of 85.1% with pembrolizumab versus 77.2% in the control group, supporting a sustained clinical benefit.23
Keytruda is currently the only immune checkpoint inhibitor approved by the FDA for the treatment of breast cancer. It earned approval in November 2020 for PD-L1-positive locally recurrent or metastatic TNBC, and in July 2021 for high-risk early-stage TNBC in the neoadjuvant or adjuvant setting. Pembrolizumab is used not only in breast cancer targeted therapies, but due to its effectiveness, it can also be used for other indications.
Atezolizumab
Atezolizumab also belongs to the class of immune checkpoint inhibitors. It acts on the same T-cell receptor, but targets the PD-L1 ligand instead of the PD-1 receptor. By occupying PD-L1 it blocks also with B7.1 (CD80), a second inhibitory partner on T cells, while sparing the PD-1-PD-L2 pairing. This blockade helps reactivate antitumor T-cell responses.24
The clinical trial provided important evidence for atezolizumab in metastatic triple-negative breast cancer. Among patients with PD-L1-positive tumors, defined using a specific assay measuring expression on tumor-infiltrating immune cells, median progression-free survival increased to 7.5 months with atezolizumab plus nab-paclitaxel versus 5.0 months with chemotherapy alone.25 Encouraging overall survival differences were observed in this subgroup, although the trial’s statistical testing strategy did not establish a confirmatory overall survival benefit. Subsequent research demonstrated that the choice of chemotherapy partner and tumor subtype mattered considerably. Clinical studies did not demonstrate the expected benefit when atezolizumab was combined with conventional paclitaxel, nor improvement in pathological complete response when atezolizumab was added to HER2-targeted antibodies and chemotherapy.26
Regulatory history of atezolizumab (Tecentriq) highlights the importance of continuously reassessing clinical evidence. The mAb was originally approved in March 2019 by the FDA and in August 2019 by the EMA for PD-L1-positive metastatic triple-negative breast cancer. The results mentioned above led to Roche’s voluntary withdrawal of the drug from the U.S. market in 2021. However, atezolizumab remains authorized in the European Union with nab-paclitaxel for selected patients.27

Antibody-Drug Conjugates Breast Cancer Targeted Therapies
Antibody-drug conjugates combine the molecular recognition capabilities of monoclonal antibodies with the destructive power of cytotoxic compounds. That is why they are often referred to as “smart chemotherapy”. Unlike an unconjugated monoclonal antibody, an ADCs contains three essential components:
- An antibody that recognizes an antigen on a cancer cell
- A chemical linker that binds the antibody to a drug
- A highly potent cytotoxic agent (payload)
The ADC has to remain stable in the bloodstream. After the antibody binds its target, the conjugate can be internalized into the cell. The linker should release the payload only inside the cancer cell, where it is cleaved by lysosomal enzymes or acidic conditions, or where the antibody itself is degraded. Processing of the ADC releases an active drug molecule that disrupts essential cellular processes.29 Typically, an ADC consists of an average of about three to eight payload molecules attached to each antibody, a value known as the drug-to-antibody ratio (DAR).30 The payload is typically a microtubule inhibitor, such as the maytansinoid (DM1), or a topoisomerase I inhibitor, such as SN-38 or the exatecan derivative (DXd).
One of the greatest advantages of ADC technology is its ability to improve the distribution of highly potent anticancer compounds toward malignant tissue. In some ADCs the released payload can cross cell membranes and damage neighboring cancer cells that express lower amounts of the target antigen. This phenomenon is called the bystander effect.31 It is particularly relevant in breast cancer, where tumors can contain cell populations with very different levels of HER2 expression. The discovery that ADCs can be effective even in tumors classified as HER2-low has expanded the population potentially eligible for HER2-directed treatments. This finding breaks with the long-held assumption that only strongly HER2-positive tumors can benefit from therapies targeting this receptor.

Antibody-drug conjugates, thanks to their properties, represent a new generation of breast cancer targeted therapies.33,34
Trastuzumab Deruxtecan and Trastuzumab Emtansine
Trastuzumab emtansine links about 3.5 molecules of the maytansinoid DM1, a microtubule inhibitor, to the antibody through a non-cleavable linker. After the complex is internalised, the antibody is degraded in the lysosome and the payload is released still attached to the linker and a lysine residue. This charged fragment that is trapped inside the cell and cannot reach its neighbours.35
Trastuzumab deruxtecan instead attaches roughly eight molecules of deruxtecan, a topoisomerase I inhibitor from the camptothecin family, through a tetrapeptide linker that is cleaved by lysosomal cathepsins. Unlike the predominantly intracellular activity of trastuzumab emtansine, trastuzumab deruxtecan can generate a pronounced bystander effect, allowing it to attack nearby cells with relatively low HER2 expression. It has a short half-life in the circulation, which limits systemic exposure.36
These structural differences translate into clinically important distinctions. The higher DAR and the bystander effect make trastuzumab deruxtecan active in tumors with heterogeneous or low HER2 expression, whereas trastuzumab emtansine is used in HER2-positive disease. Their toxicity profiles differ as well. Trastuzumab deruxtecan is associated with nausea, neutropenia and, most importantly, ILD, which requires systematic monitoring and prompt treatment interruption. Trastuzumab emtansine is mainly associated with thrombocytopenia, liver enzyme elevation and neuropathy.
Both medicines demonstrated major clinical benefits, although in different treatment settings. Trastuzumab emtansine improved median progression-free survival to 9.6 months compared with 6.4 months for lapatinib plus capecitabine in previously treated metastatic HER2-positive breast cancer.37 Patients with residual invasive disease after neoadjuvant HER2-directed treatment had a three-year invasive disease-free survival rate of 88.3% with trastuzumab emtansine versus 77.0% with trastuzumab.38 Kadcyla received FDA approval on February 2013, for late-stage metastatic breast cancer, followed by an expansion on May 2019, for early-stage adjuvant treatment.
Trastuzumab deruxtecan subsequently showed superior results in the breast cancer clinical trial, achieving median progression-free survival of approximately 28.8 months versus 6.8 months with trastuzumab emtansine.39 More recent evidence has moved trastuzumab deruxtecan into earlier treatment settings. First-line trastuzumab deruxtecan combined with pertuzumab significantly improved progression-free survival compared with taxane chemotherapy plus trastuzumab and pertuzumab. The FDA approval analysis reported median values of 40.7 versus 26.9 months, respectively.40 Enhertu received its initial FDA approval for adult patients with unresectable or metastatic HER2-positive breast cancer who received two or more prior anti-HER2-based regimens on December 2019. Since then, the drug has expanded its activity to multiple major indications across various cancer types.
Sacituzumab Govitecan
Sacituzumab govitecan is an ADC directed against TROP-2, an antigen frequently expressed in breast cancer. Structurally, it is a humanised IgG1 linked through a CL2A linker to SN-38, the active metabolite of irinotecan at a high DAR of about 7.6. ADC payload inhibits topoisomerase I, an enzyme required for DNA replication and repair. Following drug delivery and release, DNA damage accumulates, particularly in proliferating cancer cells, ultimately contributing to cell death. The payload’s membrane permeability can also generate a bystander effect.41 Because TROP-2 is found in multiple breast cancer subtypes, sacituzumab govitecan has become therapeutically relevant not only for triple-negative disease but also for selected patients with hormone receptor (HR)-positive or HER2-negative metastatic breast cancer.42
In the clinical trial compared sacituzumab govitecan with physician-selected chemotherapy in patients with previously treated metastatic TNBC. The study showed median progression-free survival of 5.6 versus 1.7 months and median overall survival of 12.1 versus 6.7 months compared with single-agent chemotherapy.43 These data led to full FDA approval in April 2021 (initially granted accelerated approval in April 2020).
In hormone receptor-positive, HER2-negative disease, the clinical trial in 543 heavily pretreated patients recorded median progression-free survival of 5.5 versus 4.0 months and overall survival of 14.4 versus 11.2 months.44 The FDA approved Trodelvy for this indication in February 2023.
The role of sacituzumab govitecan expanded again in 2026, when the FDA approved its use as a first-line treatment for selected patients with advanced TNBC. In that clinical trial, sacituzumab govitecan monotherapy achieved median progression-free survival of 9.7 months versus 6.9 months with standard chemotherapy among patients who were not candidates for PD-1 or PD-L1 inhibition.45 Another study, combining sacituzumab govitecan with pembrolizumab improved median progression-free survival to 11.2 months versus 7.8 months with pembrolizumab plus conventional chemotherapy in PD-L1-positive metastatic TNBC.46 The European Commission also expanded the monotherapy indication for first-line patients ineligible for checkpoint inhibitors, while the CHMP recommended the pembrolizumab combination in July 2026.
Innovative Breast Cancer Targeted Therapies on the Horizon
Innovative breast cancer targeted therapies are shifting toward next-generation precision medicine. The development of new drug modalities is driven by bispecific antibodies, tumor-infiltrating lymphocyte (TIL) therapies, chimeric antigen receptor T-cell (CAR-T) therapies, and mutant-selective inhibitors.
Bispecific antibodies are engineered to bind two different targets or two different epitopes. Zanidatamab is a HER2-directed bispecific of the biparatopic type. One arm binds subdomain II, the pertuzumab epitope, and the other binds subdomain IV, the trastuzumab epitope. That way a single molecule can bridge two HER2 receptors in a trans configuration. This clusters the receptors into larger complexes, which accelerates their internalisation and downregulation. Zanidatamab blocks signalling more completely than either antibody alone and, unlike trastuzumab or pertuzumab, also activates CDC in addition to ADCC and phagocytosis.47 In August 2026 the FDA approves zanidatamab in combination with tislelizumab and chemotherapy for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma. This offers hope that this therapy could also be used to treat HER2-positive breast cancer.
The second promising modality is cell therapy with tumor-infiltrating lymphocytes. TIL therapy involves collecting tumor tissue, isolating lymphocytes, selecting or enriching cells with antitumor activity where appropriate, and expanding them outside the body under specialized culture conditions. After preparative treatment designed to support the transferred cells, the expanded lymphocytes are infused back. The patient receives lymphodepleting chemotherapy, which clears space and removes regulatory T cells, and the expanded cells are typically infused together with interleukin-2 and often a PD-1 inhibitor that prevents them from becoming exhausted again. These cells may then recognize malignant cells through their natural T-cell receptors and destroy them through cytotoxic mechanisms involving perforin and granzymes.48,49
CAR-T therapy, takes the logic one step further by building the receptor rather than finding it. A patient’s T cells are collected and genetically modified. Further expression of the chimeric antigen receptor that combines the antigen-binding domain of an antibody with the intracellular signalling domains of a T-cell receptor and co-stimulatory molecules, expanded and infused back as a living drug. CAR-T cells have transformed haematological malignancies, but solid or breast cancer among them, are far harder. There are few antigens that are absent from normal tissue, the tumor microenvironment is hostile, trafficking into the tumor is inefficient, and antigen levels vary from cell to cell.50 Modern technologies, including advanced gene editing, synthetic biology, vector engineering, and sophisticated cell-manufacturing processes, are enabling the development of CAR-T cells with dual-antigen recognition, improved persistence, and potentially greater resistance to immunosuppressive tumor environments.
Mutant-selective inhibitors are a new class of targeted oral drugs designed to block mutated PI3Kα enzymes while sparing normal, healthy cells in HR-positive and HER2-negative breast cancer. Unlike non-selective drugs that attach to the standard active site, mutant-selective inhibitors bind to a unique allosteric site found only on the mutated version of the protein. This is a very specific class of anticancer drugs.51
FAQ
Prepared by:

Marketing Specialist
References
- Ferlay J, Lam F, Laversanne M, Colombet M, Mery L, Piñeros, M. Global Cancer Observatory: Cancer Today (Website). International Agency for Research on Cancer. 2026.
- Sung H, Filho AM, Laversanne M, Ferlay J, Siegel RL, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA Cancer J Clin. 2026; 76(4): e70090.
- European Cancer Information System. Female Breast Cancer in EU27/EFTA Countries in 2024 (Factsheet). European Commission. 2026.
- Kim J, Harper A, McCormack V, Sung H, Houssami N, Morgan E, Mutebi M, Garvey G, Soerjomataram I, Fidler-Benaoudia MM. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med. 2025; 31(4): 1154-1162.
- Orrantia-Borunda E, Anchondo-Nuñez P, Acuña-Aguilar LE, Gómez-Valles FO, Ramírez-Valdespino CA. Subtypes of Breast Cancer. [in:] Mayrovitz HN (ed.). Breast Cancer. Exon Publications. Brisbane. 2022.
- Riaz Z. Comprehensive Analysis of Antibody Structure and Function. AssayGenie. 2025.
- Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11): 783-792.
- Maadi H, Soheilifar MH, Choi WS, Moshtaghian A, Wang Z. Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma. Cancers (Basel). 2021; 13(14): 3540.
- Petricevic B, Laengle J, Singer J, Sachet M, Fazekas J, Steger G, Bartsch R, Jensen-Jarolim E, Bergmann M. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. J Transl Med. 2013; 11: 307.
- Early Breast Cancer Trialists’ Collaborative group (EBCTCG). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol. 2021;22(8):1139-1150.
- Conte B, Montemurro F, Levaggi A, Blondeaux E, Molinelli C, Cardinali B, Poggio F, Buzzatti G, Bighin C, Lambertini M, Del Mastro L. Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial. Tumori. 2023; 109(1): 71-78.
- Triantafyllidi E, Triantafillidis JK. Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer. Biomedicines. 2022; 10(8): 2045.
- Lamond NW, Younis T. Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations. Int J Womens Health. 2014; 6: 509-521.
- Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer. 2007; 97(4): 453-457.
- Dai WF, Beca JM, Nagamuthu C, Liu N, de Oliveira C, Earle CC, Trudeau M, Mercer RE, Chan KKW. Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer. JAMA Netw Open. 2022; 5(2): e2145460.
- Yang J, Lin L, Long Q, Zhang Q, Sun G, Zhou L, Wang Q, Zhu J, Li F, Hu W. HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects. BioDrugs. 2022; 36(3): 393-409.
- Gradishar WJ, O’Regan R, Rimawi MF, Nordstrom JL, Rosales MK, Rugo HS. Margetuximab in HER2-positive metastatic breast cancer. Future Oncol. 2023; 19(16): 1099-1112.
- Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, Pegram MD, Bachelot T, Wright GS, Saura C, Escrivá-de-Romaní S, De Laurentiis M, Schwartz GN, Pluard TJ, Ricci F, Gwin WR 3rd, Levy C, Brown-Glaberman U, Ferrero JM, de Boer M, Kim SB, Petráková K, Yardley DA, Freedman O, Jakobsen EH, Gal-Yam EN, Yerushalmi R, Fasching PA, Kaufman PA, Ashley EJ, Perez-Olle R, Hong S, Rosales MK, Gradishar WJ; SOPHIA Study Group. Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial. J Clin Oncol. 2023; 41(2): 198-205.
- Royce M, Osgood CL, Amatya AK, Fiero MH, Chang CJG, Ricks TK, Shetty KA, Kraft J, Qiu J, Song P, Charlab R, Yu J, King KE, Rastogi A, Janelsins B, Weinberg WC, Clouse K, Borders-Hemphill V, Brown L, Gomez-Broughton C, Li Z, Nguyen TT, Qiu Z, Ly AT, Chang S, Gao T, Tu CM, King-Kallimanis B, Pierce WF, Chiang K, Lee C, Goldberg KB, Leighton JK, Tang S, Pazdur R, Beaver JA, Amiri-Kordestani L. FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer. Clin Cancer Res. 2022; 28(8): 1487-1492.
- Oh DY, Bang YJ. HER2-targeted therapies – a role beyond breast cancer. Nat Rev Clin Oncol. 2020; 17(1): 33-48.
- Na Z, Yeo SP, Bharath SR, Bowler MW, Balıkçı E, Wang CI, Song H. Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab. Cell Res. 2017; 27(1): 147-150.
- Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P; KEYNOTE-355 Investigators. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2022; 387(3): 217-226.
- Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kümmel S, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Hou S, Malhotra U, Beca F, O’Shaughnessy J. Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Final analysis results from the phase 3 KEYNOTE-522 study. J. Clin. Oncol. 2026; 44(16): 507.
- Saleh R, Taha RZ, Sasidharan Nair V, Alajez NM, Elkord E. PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer. Cancers (Basel). 2019; 11(8): 1050.
- Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Trial Investigators. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22): 2108-2121.
- Latif F, Bint Abdul Jabbar H, Malik H, Sadaf H, Sarfraz A, Sarfraz Z, Cherrez-Ojeda I. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis. Expert Rev Anticancer Ther. 2022; 22(2): 229-235.
- Poland S. Lessons From the Withdrawal of Atezolizumab in Metastatic TNBC. Cancer Network. 2026.
- Centanni M, Moes DJAR, Trocóniz IF, Ciccolini J, van Hasselt JGC. Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors. Clin Pharmacokinet. 2019; 58(7): 835-857.
- Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct Target Ther. 2022; 7(1): 93.
- Inoue K, Mochizuki T, Kasamori N, Komori T. Determination of drug-to-antibody ratio of antibody-drug conjugate in biological samples using microflow-liquid chromatography/high-resolution mass spectrometry. Bioanalysis. 2022; 14(24): 1533-1545.
- Wang Y, Cheng X, Li X, Chen W, Zhang X, Liu Y. Bystander effect in antibody-drug conjugates: Navigating the fine line in tumor heterogeneity. Crit Rev Oncol Hematol. 2025; 216: 104979.
- Knurek J. Breaking Barriers in Antibody-Drug Conjugates Development. Mabion Science Hub. 2026.
- Lv Y, Cui X, Li T, Liu C, Wang A, Wang T, Zhou X, Li R, Zhang F, Hu Y, Zhang T, Liu Z. Mechanism of action and future perspectives of ADCs in combination with immune checkpoint inhibitors for solid tumors. Clin Exp Med. 2025; 25(1): 139.
- He J, Zeng X, Wang C, Wang E, Li Y. Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies. MedComm (2020). 2024; 5(8): e671.
- He J, Yu SF, Yee S, Kaur S, Xu K. Characterization of in vivo biotransformations for trastuzumab emtansine by high-resolution accurate-mass mass spectrometry. MAbs. 2018; 10(7): 960-967.
- Martín M, Pandiella A, Vargas-Castrillón E, Díaz-Rodríguez E, Iglesias-Hernangómez T, Martínez Cano C, Fernández-Cuesta I, Winkow E, Perelló MF. Trastuzumab deruxtecan in breast cancer. Crit Rev Oncol Hematol. 2024; 198: 104355.
- Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012; 367(19): 1783-1791.
- Wedam S, Fashoyin-Aje L, Gao X, Bloomquist E, Tang S, Sridhara R, Goldberg KB, King-Kallimanis BL, Theoret MR, Ibrahim A, Amiri-Kordestani L, Pazdur R, Beaver JA. FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer. Clin Cancer Res. 2020; 26(16): 4180-4185.
- Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, Chiu JWY, Xu B, Hamilton E, Madhusudan S, Iwata H, Altintas S, Henning JW, Curigliano G, Perez-Garcia JM, Kim SB, Petry V, Huang CS, Li W, Frenel JS, Antolin S, Yeo W, Bianchini G, Loi S, Tsurutani J, Egorov A, Liu Y, Cathcart J, Ashfaque S, Cortés J. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023; 401(10371): 105-117.
- Tolaney SM, Jiang Z, Zhang Q, Barroso-Sousa R, Park YH, Rimawi MF, Saura C, Schneeweiss A, Toi M, Chae YS, Kemal Y, Chaudhari M, Şendur MAN, Yamashita T, Casalnuovo M, Danso MA, Liu J, Shetty J, Herbolsheimer P, Loibl S; DESTINY-Breast09 Trial Investigators. Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2026; 394(6): 551-562.
- Tolaney SM, Cardillo TM, Chou CC, Dornan C, Faris M. The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid Tumors. Clin Cancer Res. 2025; 31(8): 1390-1399.
- Lombardi P, Filetti M, Falcone R, Altamura V, Paroni Sterbini F, Bria E, Fabi A, Giannarelli D, Scambia G, Daniele G. Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings. Cancers (Basel). 2023; 15(6): 1744.
- Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O’Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021; 384(16): 1529-1541.
- Xu B, Wang S, Yan M, Sohn J, Li W, Tang J, Wang X, Wang Y, Im SA, Jiang D, Valdez T, Dasgupta A, Zhang Y, Yan Y, Komatsubara KM, Chung WP, Ma F, Dai MS. Sacituzumab govitecan in HR+HER2– metastatic breast cancer: the randomized phase 3 EVER-132-002 trial. Nat Med. 2024; 30(12): 3709-3716.
- Cortés J, Punie K, Barrios C, Hurvitz SA, Schneeweiss A, Sohn J, Tokunaga E, Brufsky A, Park YH, Xu B, Hegg R, Oliveira M, Fabi A, Vaksman N, Valdez T, Zhang X, Lai C, Tolaney SM; ASCENT-03 Clinical Trial Investigators. Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer. N Engl J Med. 2025; 393(19): 1912-1925.
- Tolaney SM, de Azambuja E, Kalinsky K, Loi S, Kim SB, Yam C, Rapoport B, Im SA, Pistilli B, Mchayleh W, Cescon DW, Watanabe J, Bañuelas MAL, Freitas-Junior R, Salvador Bofill J, Afshari M, Gary D, Wang L, Lai C, Schmid P; ASCENT-04/KEYNOTE-D19 Clinical Trial Investigators. Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. N Engl J Med. 2026; 394(4): 354-366.
- Valero V, Pohlmann PR, Mouabbi J, Huang X, Qiao W, Alonzo H, Murthy RK, Rauch GM, Adesoye T, Checka C, Symmans FW, Grachev D, Alajajyan F, Nwosu-Iheme A, Hassan A, Patel M, Giordano SH, Hunt K, Tripathy D, Meric-Bernstam F. Zanidatamab in patients with early stage HER2-positive breast cancer: the NeoZanHER phase 2 single-arm open-label trial. Nat Commun. 2026; 17(1): 10116.
- Finkelman BS, Zhang H, Hicks DG, Rimm DL, Turner BM. Tumor infiltrating lymphocytes in breast cancer: A narrative review with focus on analytic validity, clinical validity, and clinical utility. Hum Pathol. 2025; 162: 105866.
- Wang Y, Zhang Z, Chen Z, Xie X, Wang F. Tumor-infiltrating lymphocyte therapy in triple-negative breast cancer: from mechanistic exploration to clinical translation. Front Immunol. 2026; 17: 1741333.
- Yang YH, Liu JW, Lu C, Wei JF. CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application. Int J Biol Sci. 2022; 18(6): 2609-2626.
- Vanhaesebroeck B, Burke JE, Madsen RR. Precision Targeting of Mutant PI3Kα in Cancer by Selective Degradation. Cancer Discov. 2022; 12(1): 20-22.


